IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas
- 1 September 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 64 (CN_suppl_1) , 134-138
Abstract
No abstract availableFunding Information
- National Institutes of Health (P50CA165962)
- Burroughs Wellcome Fund (1007616.02)
This publication has 64 references indexed in Scilit:
- Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysisJournal of Neuro-Oncology, 2013
- The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomasJournal of Neuro-Oncology, 2012
- 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomasNature Medicine, 2012
- Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from ChinaPLOS ONE, 2012
- Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of OriginJournal of Clinical Oncology, 2011
- Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyJournal of Neuro-Oncology, 2011
- The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastomaActa Neuropathologica, 2010
- IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomasNeuro-Oncology, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008